L. Morales

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 729 citations · Full text

Medicine, Oncology, Pharmacology +17

Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial

Scott E. Kasner, Balakumar Swaminathan, Pablo M. Lavados et al. · The Lancet Neurology · 2018 · 178 citations · Full text

Medicine, Neurology, Pharmacotherapy +17

Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer

R. Bell, Julia Brown, Mahesh Parmar et al. · Annals of Oncology · 2016 · 104 citations · Full text

Medicine, Oncology, Breast Oncology +9

LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)

D.W. Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2020 · 97 citations

Medicine, Oncology, Pharmacology +16

Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients

L. Morales, D. Timmerman, Patrick Neven et al. · Annals of Oncology · 2004 · 57 citations

Medicine, Oncology, Pharmacology +17